Promotional pieces should reveal risks material to the specific benefit claims made

AI-verifiedwarningFDA guidance · non-bindingRaised as a question — a person decides

Rule

When a piece makes a specific benefit claim (e.g., about a dosing regimen, a patient subgroup), it should disclose the risks that are material to that specific claim.

Check

For each distinct benefit claim in the piece, identify the risks specifically material to that claim (e.g., risks tied to the regimen or population highlighted) and confirm they are disclosed.

Escalate when

When a benefit claim highlights a specific feature or population and the risks tied to that specific feature/population are not disclosed.

Where this comes from

Section III.B.2, The Nature of Benefit Claims · page 16. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…s with other drugs or food. Risks conveyed only in the adverse events or side effects section are generally less serious or less well-documented than those in the preceding three categories. They are often the most commonly experienced risks associated with a product, however, and they therefore may constitute important information for both healthcare professionals and consumers. • The Nature of Benefit Claims Promotional pieces should reveal risk information that is material in light of the specific benefit claims made in the piece. Example 12: If a piece claims convenience because the promoted drug is dosed once-weekly, information about risks directly related to the regimen’s convenience is material. Such risk information might include, for example, that inflammatory reactions such as swelling have been reported at the application site for a topical product, or that patients must restrict their activities for some time after taking an …

Open the original at page 16 on fda.gov ↗Read our full copy →

Document: FDA guidance: Presenting Risk Information in Prescription Drug and Medical Device Promotion (see document)
Version: as retrieved — the publisher does not version this document; the fingerprint below identifies the exact file
Retrieved: 2026-09-21 from www.fda.gov
Fingerprint: f5654ab082f6cd4408143f16…

FDA guidance describes the agency's current thinking. It is not binding law, and this rule is a recommendation, not an obligation.

Applies when

Naturepromotional

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-code:sonnet · 2026-09-21
Independent verification — pass
claude-code:opus · 2026-09-21
Reviewer's reasons
- Supported: the quote is the operative topic sentence of the 'Nature of Benefit Claims' discussion — 'Promotional pieces should reveal risk information that is material in light of the specific benefit claims made in the piece' — not an example or a description of what is not required.
- Not overstated: the rule preserves 'should' and does not broaden the materiality standard into a requirement to disclose all risks.
- The illustrative parentheticals ('a dosing regimen, a patient subgroup') do not rest the requirement on Examples 12 and 13; the patient-class case is separately stated in operative text ('for promotional pieces that promote a product's benefits in a selected class of patients, the significant risks applicable to that class of patients are material'), so the rule's scope is grounded.
- Atomic: one requirement — risks material to the benefit claims actually made are disclosed. It is applied per claim rather than bundling independent obligations.
- 'judgment' is correct: materiality in light of a benefit claim is an assessment, not a literal match.
- Authority 'guidance' matches the source document. Category 'risk-disclosure', severity 'warning' and the 'promotional' scope are appropriate; the surrounding text applies to both healthcare professional and consumer audiences, so no audience limit is missing.
- The locator is right: 'The Nature of Benefit Claims' is a sub-heading within Section III.B.2 (Materiality and Comprehensiveness). The quote is a whole sentence with its subject intact.
Revised by the drafter
claude-code:sonnet · 2026-09-21
Independent verification — revise
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote is a complete sentence under 'The Nature of Benefit Claims' in Section III.B.2 (Materiality and Comprehensiveness), and it supports the rule. The examples in the rule text (dosing regimen, patient subgroup) come from Examples 12 and 13 and from the sentence 'for promotional pieces that promote a product's benefits in a selected class of patients, the significant risks applicable to that class of patients are material.'
- The rule body and check say 'should', which is faithful. The title 'Disclose risks material to the specific benefit claims made' is a bare imperative. It turns the guidance's 'should reveal' into a directive.
- 'judgment' is correct because materiality turns on a reasonable member of the target audience. The rule is atomic, and the locator, applies_when and 'warning' severity are defensible.
Revised by the drafter
claude-code:sonnet · 2026-09-21
Independent verification — pass
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote 'Promotional pieces should reveal risk information that is material in light of the specific benefit claims made in the piece.' is a verbatim whole sentence under 'The Nature of Benefit Claims' in Section III.B.2 (Materiality and Comprehensiveness). The locator is correct.
- The rule's examples (a dosing regimen, a patient subgroup) track Examples 12 and 13 and the following text on selected patient classes. The rule keeps 'should', so it is not overstated.
- The rule is a single recommendation, so it is atomic. Judgment is correct because materiality relative to a claim is an assessment.
- The promotional scope and the warning severity are appropriate.
- Minor, not required: the 'Escalate when' text describes the finding itself rather than an ambiguous case.